Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
QIFENG
873169
5
LAISAI LASER
871263
CN Stock MarketDetailed Quotes
301201 Chengda Pharmaceuticals
- 21.30
- -0.85-3.84%
Market Closed May 9 15:00 CST
3.30BMarket Cap-68.49P/E (TTM)
25.19High21.18Low134.99KlotVolume24.40Open22.15Pre Close310.38MTurnover15.48%Turnover RatioLossP/E (Static)154.71MShares26.5252wk High1.54P/B1.86BFloat Cap16.5052wk Low26.58Limit Up87.19MShs Float116.84Historical High17.72Limit Down18.10%Amplitude14.40Historical Low0.20Dividend TTM22.99Avg Price70.99KlotAsk0.94%Div YieldTTM100Lot Size55.62KlotBid
About Chengda Pharmaceuticals Company
The company was founded in 1999 and listed on the Shenzhen Stock Exchange in 2022. The company is committed to providing CDMO services for multinational pharmaceutical companies and pharmaceutical R&D institutions such as process development and optimization, quality research and customized production of key pharmaceutical intermediates and APIs in the clinical trial and commercialization stages. The terminal drugs cover various treatment fields such as antitumor, antiviral, neurological, and diabetes. The company's main business covers providing CDMO R&D and production services for key pharmaceutical intermediates and pharmaceutical R&D institutions, R&D, production and sales of L-carnitine series products and APIs, and R&D of stem cell drugs for multinational pharmaceutical companies and pharmaceutical R&D institutions. The company's main products are L-carnitine, L-carnitine hydrochloride, acetyl L-carnitine hydrochloride, DL-carnitine hydrochloride, L-carnitine tartrate, L-carnitine fumarate, L-carnitine (50%), and raw materials. Corporate honors: In 2023, it won the second batch of benchmark projects in Zhejiang Province - pollution reduction and carbon reduction project, Jiaxing city fire “five advanced” pilot units, Jiaxing key enterprise compliance construction pilot units, the 17th Jiashan County Mayor Quality Award, high-tech enterprise certificate, national key new product (L-carnitine) certificate, “Yangtze River Delta Ecological Green Integrated Development Demonstration Zone Green Development Leading Enterprise”, the 2024 Zhejiang Green Low-carbon Factory, Jiashan County “Safety Production Demonstration Enterprise”, etc.
Company Profile
Short Name-A诚达药业
Symbol-A301201
Company NameChengDa Pharmaceuticals Co.,Ltd.
Listing DateJan 20, 2022
Issue Price72.69
Shares Offered24.17M share(s)
FoundedJun 30, 1980
Legal Representativejianli ge
General Managergang lu
Secretaryxiaojing yang
Accounting FirmZhonghua Certified Public Accountants (Special General Partnership)
Securities Representativezhongjie wu
Legal CounselBeijing Zhonglun Wende (Hangzhou) Law Firm
Employees599
Phone0573-84468033
Office AddressNo. 36 Huanghe Road, Huimin Street, Jiashan County, Jiaxing City, Zhejiang Province
Zip Code314100
Registered AddressNo. 36 Huanghe Road, Huimin Street, Jiashan County, Jiaxing City, Zhejiang Province
Fax0573-84185902
Emailir@chengdapharm.com
Websitehttp://www.chengdapharm.com/
Business License330400400005966
BusinessProduction of raw materials (operated under the “Pharmaceutical Production License of the People's Republic of China”), production and sale of food additives (operated under the “National Industrial Product Production License”), feed additives (operated under the “Feed Additives Production License”), pharmaceutical intermediate chemical raw materials and chemical products (excluding easy-to-make drugs, which involve only production and storage of chemical dangerous goods, and operated under the “Jiaxing Dangerous Chemicals Production and Storage Approval Certificate”), technology research and development and transfer of technical results for APIs and pharmaceutical intermediates. (For projects requiring approval according to law, business activities can only be carried out after approval by relevant departments)
Company Executives
- Name
- Position
- Salary
- jianli ge
- Chairman, Directors, Nomination Committee Members, Strategy Committee Convener
- 602.70K
- gang lu
- Directors, General Manager, Member of the Remuneration and Assessment Committee, Strategy Committee Member
- 668.80K
- jin lu
- Directors, Deputy General Manager
- 619.80K
- honglin huang
- Directors, Deputy General Manager
- 450.10K
- yi yu
- Independent Directors, Audit Committee Member, Remuneration and Assessment Committee Convener
- 72.00K
- sunliang cui
- Independent Directors, Nomination Committee Convener, Strategy Committee Member, Audit Committee Member
- 72.00K
- ping wang
- Independent Directors, Nomination Committee Members, Member of the Remuneration and Assessment Committee, Audit Committee Convener
- 72.00K
- xiaojing yang
- Board Secretary, Deputy General Manager
- 351.00K
- zhongjie wu
- Securities Affairs Representative
- --
- weihan chen
- Chairman of the Supervisory Board, Employee Supervisors
- 202.00K
- zhan su
- Auditors
- 149.50K
- yu feng
- Deputy General Manager
- 793.10K
- zhiyong peng
- Deputy General Manager
- 560.40K
- bao hu
- Deputy General Manager
- 446.60K
- minwei zhao
- Deputy General Manager
- 146.10K
- chao fei
- Chief Financial Officer
- 308.70K
- wenjuan li
- Employee Supervisors
- 130.30K
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting